Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.8532.2700
Address
4-6 Southampton Crescent Abbotsford, Victoria (VIC) 3067
Description
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The firm's programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.09 - 0.2
Trade Value (12mth)
AU$24,151.00
1 week
-3.06%
1 month
-0.52%
YTD
-45.71%
1 year
-38.71%
All time high
2.52
EPS 3 yr Growth
-60.20%
EBITDA Margin
-169.40%
Operating Cashflow
-$7m
Free Cash Flow Return
-20.60%
ROIC
-24.10%
Interest Coverage
N/A
Quick Ratio
4.60
Shares on Issue (Fully Dilluted)
412m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.23
Date | Announcements |
---|---|
02 September 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
02 September 24 |
Change in Director's Interest Notice - David McIntyre
×
Change in Director's Interest Notice - David McIntyre |
28 August 24 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
27 August 24 |
Change in substantial holding
×
Change in substantial holding |
22 August 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
22 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
16 August 24 |
Change in substantial holding
×
Change in substantial holding |
02 August 24 |
Change in substantial holding
×
Change in substantial holding |
30 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
02 July 24 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
02 July 24 |
Change in substantial holding
×
Change in substantial holding |
01 July 24 |
Change in Director's Interest Notice - Jeff Davies
×
Change in Director's Interest Notice - Jeff Davies |
28 June 24 |
Change in substantial holding
×
Change in substantial holding |
27 June 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
27 June 24 |
Change in Director's Interest Notice - L Cheng
×
Change in Director's Interest Notice - L Cheng |
25 June 24 |
Change in substantial holding
×
Change in substantial holding |
21 June 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
11 June 24 |
Notification regarding unquoted securities - SPL
×
Notification regarding unquoted securities - SPL |
11 June 24 |
DEP presentation at SNMMI radiopharmaceuticals conference
×
DEP presentation at SNMMI radiopharmaceuticals conference |
04 June 24 |
DEP irinotecan presentation at ASCO 2024 Annual Meeting
×
DEP irinotecan presentation at ASCO 2024 Annual Meeting |
03 June 24 |
DEP cabazitaxel presentation at ASCO 2024 Annual Meeting
×
DEP cabazitaxel presentation at ASCO 2024 Annual Meeting |
30 May 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
30 May 24 |
Change in Director's Interest Notice - Cheryl Maley
×
Change in Director's Interest Notice - Cheryl Maley |
27 May 24 |
Positive final DEP irinotecan Phase 2 clinical trial results
×
Positive final DEP irinotecan Phase 2 clinical trial results |
22 May 24 |
Starpharma Business Update
×
Starpharma Business Update |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.